In the News
Managing risks from skin exposure at work (HSG262). The guidance in this edition has been refreshed and references updated.
The medical examination and assessment of commercial divers (MA1). This document replaces the previous version of MA1 published in December 2011.
The European Chemical Agency (ECHA) has announced withdrawal of support for Didecyldimethylammonium chloride (DDAC (C8-10)) (product type 5), Performic acid generated from formic acid and hydrogen peroxide (product types 3, 5 and 6), Formic acid (product types 11 and 12) and Silver Copper Zeolite (product type 5) from the biocides active substance review programme
ECHA has published an open invitation which allows interested companies to take over the role of participant for the above active substance/product type combinations. Interested companies should complete the notification procedure in Article 17 of the Review Regulation by the 30 September 2016. Notifications should be submitted to the European Chemicals Agency (ECHA), via R4BP .
If no-one takes over the role of participant, these active substance/product type combinations will be subject to a non-approval decision and products containing them for the affected product types will have to be removed from the market.
(Source: https://idp-industry.echa.europa.eu/idp/)